Currently, there are 39.74M common shares owned by the public and among those 27.91M shares have been available to trade.
The company’s stock has a 5-day price change of 5.03% and -30.19% over the past three months. VIRX shares are trading -71.44% year to date (YTD), with the 12-month market performance down to -66.71% lower. It has a 12-month low price of $0.13 and touched a high of $1.31 over the same period. VIRX has an average intraday trading volume of 1.11 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.14%, -19.01%, and -69.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Viracta Therapeutics Inc (NASDAQ: VIRX) shares accounts for 13.00% of the company’s 39.74M shares outstanding.
It has a market capitalization of $6.47M and a beta (3y monthly) value of 0.68. The earnings-per-share (ttm) stands at -$1.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.33% over the week and 10.61% over the month.
Earnings per share for the fiscal year are expected to increase by 31.57%, and 43.91% over the next financial year.
Looking at the support for the VIRX, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on August 16, 2024, with the firm’s price target at $5-$3. RBC Capital Mkts coverage for the Viracta Therapeutics Inc (VIRX) stock in a research note released on February 01, 2022 offered a Outperform rating with a price target of $10. H.C. Wainwright was of a view on May 03, 2021 that the stock is Buy, while SVB Leerink gave the stock Outperform rating on April 26, 2021, issuing a price target of $18. Evercore ISI on their part issued Outperform rating on March 25, 2021.
